Skip to content
The Policy VaultThe Policy Vault

Lorbrena (lorlatinib) — Medica

Large B-Cell Lymphoma

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has anaplastic lymphoma kinase (ALK)-positive disease
  • Patient has relapsed or refractory disease

Approval duration

1 year